These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 16294183)

  • 21. Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia.
    Rugolotto S; Errico G; Beghini R; Ilic S; Richelli C; Padovani EM
    Minerva Pediatr; 2006 Oct; 58(5):491-4. PubMed ID: 17008861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pulmonary hypertension: new perspectives.
    Nauser TD; Stites SW
    Congest Heart Fail; 2003; 9(3):155-62. PubMed ID: 12826774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K; Savale L; O'Callaghan DS; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epoprostenol Therapy for Pulmonary Arterial Hypertension.
    Akagi S; Nakamura K; Matsubara H; Ogawa A; Sarashina T; Ejiri K; Ito H
    Acta Med Okayama; 2015; 69(3):129-36. PubMed ID: 26101188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pulmonary arterial hypertension: a current review of pharmacological management.
    Sahni S; Ojrzanowski M; Majewski S; Talwar A
    Pneumonol Alergol Pol; 2016; 84(1):47-61. PubMed ID: 26693827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic treatment for pulmonary arterial hypertension.
    Sastry BK
    Curr Opin Cardiol; 2006 Nov; 21(6):561-8. PubMed ID: 17053404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of long-term bosentan in children with pulmonary arterial hypertension.
    Rosenzweig EB; Ivy DD; Widlitz A; Doran A; Claussen LR; Yung D; Abman SH; Morganti A; Nguyen N; Barst RJ
    J Am Coll Cardiol; 2005 Aug; 46(4):697-704. PubMed ID: 16098438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pulmonary arterial hypertension.
    Montani D; Günther S; Dorfmüller P; Perros F; Girerd B; Garcia G; Jaïs X; Savale L; Artaud-Macari E; Price LC; Humbert M; Simonneau G; Sitbon O
    Orphanet J Rare Dis; 2013 Jul; 8():97. PubMed ID: 23829793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.
    Bendayan D; Shitrit D; Kramer MR
    Respirology; 2008 Nov; 13(6):916-8. PubMed ID: 18811891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV and pulmonary arterial hypertension: a systematic review.
    Janda S; Quon BS; Swiston J
    HIV Med; 2010 Nov; 11(10):620-34. PubMed ID: 20408888
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings.
    Ivy DD; Rosenzweig EB; Lemarié JC; Brand M; Rosenberg D; Barst RJ
    Am J Cardiol; 2010 Nov; 106(9):1332-8. PubMed ID: 21029834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes in pulmonary arterial hypertension in the first-line epoprostenol or first-line bosentan era.
    Jacobs W; Boonstra A; Brand M; Rosenberg DM; Schaaf B; Postmus PE; Vonk Noordegraaf A
    J Heart Lung Transplant; 2010 Oct; 29(10):1150-8. PubMed ID: 20580264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New and future therapies in pulmonary arterial hypertension.
    Bull TM
    Semin Respir Crit Care Med; 2005 Aug; 26(4):429-36. PubMed ID: 16121320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pulmonary arterial hypertension in childhood].
    Douwes JM; van Loon RL; Roothooft MT; Berger RM
    Ned Tijdschr Geneeskd; 2011; 155(49):A3901. PubMed ID: 22166180
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
    Beghetti M; Galiè N
    J Am Coll Cardiol; 2009 Mar; 53(9):733-40. PubMed ID: 19245962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
    McLaughlin V; Humbert M; Coghlan G; Nash P; Steen V
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii25-31. PubMed ID: 19487219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
    Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cost-effectiveness of bosentan in the United Kingdom for patients with pulmonary arterial hypertension of WHO functional class III.
    Stevenson MD; Macdonald FC; Langley J; Hunsche E; Akehurst R
    Value Health; 2009; 12(8):1100-5. PubMed ID: 19558373
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Initial experience with bosentan (Tracleer) as treatment for pulmonary arterial hypertension (PAH) due to congenital heart disease in infants and young children.
    Gilbert N; Luther YC; Miera O; Nagdyman N; Ewert P; Berger F; Lange PE; Schulze-Neick I
    Z Kardiol; 2005 Sep; 94(9):570-4. PubMed ID: 16142516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.